The cytology market will register a CAGR of nearly 7% by 2022.
The screening of cervical cancer has reduced the morbidity and mortality drastically. The Pap test is used as a screening tools for cervical cancer has improved detection of cervical intraepithelial neoplasia. Furthermore, increasing prevalence of HPV-associated cancers is likely to drive the market. Therefore, a substantial increase of HPV-associated cancers propels the demand for cytology testing and screenings methods. Furthermore, co-testing helps manage women who have low grade abnormal cell changes.
Growing cervical cancer screening awareness
Cervical cancer is the most common in developing as well as developing countries. It is mainly caused by human papillomavirus infection. Screening of cervical cancerous cells in mainly done by using liquid-based cytology test and Pap smear test. The increasing prevalence of cervical cancer cases have increased the demand for cytology testing.
Factors affecting adequacy of test
Poor fixation, techniques, inflammatory changes, and cellular changes related to radiation may obscure cells and cause misinterpretation of the result. This had led to false positive diagnostics which can occur in case of pregnancy, contamination of the sample, and others. Such factors will affect the adequacy of the test result and hence negatively affect the market.
The global cytology market is extremely concentrated with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.
The latest trend gaining momentum in the market is the increasing awareness and screening initiatives for HPV co-testing and benefits of early diagnostics of the disease are likely to increase the demand for cytology testing marketing.
According to the report, one of the major drivers for this market is the growing preference for liquid-based cytology tests. Further, the report states that one of the major factors hindering the growth of this market is air dying artefacts, diagnostic pitfalls and false negatively results that affect the overall adequacy of the test, thus negatively impacting the market growth.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: CUSTOMER LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Assay kits
PART 09: MARKET SEGMENTATION BY END-USER
- Comparison by end-user
- Hospitals and clinics
- Research laboratories and academic institutes
- Market opportunity by end-user
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation mainly was the word
- Regional comparison
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- Growing popularity of co-testing
- Consolidation and automation of laboratories
- Advent of cytology imaging systems
PART 14: VENDOR LANDSCAPE
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- F. Hoffmann-La Roche
- Thermo Fisher Scientific
- Trivitron Healthcare
For more information about this report visit https://www.researchandmarkets.com/research/977gj8/global_cytology?w=4